Wilson's disease is an autosomal recessive trait, which means that the patient must have inherited one copy of the defective gene from each parent in order to be affected. If a patient only has one faulty gene, he or she will not become ill, but will be a carrier and can pass the gene on to their children. Wilson's disease symptoms typically appear between the ages of 12 and 23, according to National Library of Medicine data, and untreated patients can live for up to 40 years. On the other hand, early detection and treatment of Wilson's disease may help people live longer lives. Because copper is not properly eliminated in Wilson's disease, it accumulates in the body above normal levels. Wilson's disease symptoms are most common between the ages of 12 and 23. Symptoms include swelling, fatigue, stomach pain, and uncontrolled or poorly coordinated motions.
Furthermore, medications such as D-Penicillamine and Trientine are frequently used in treatment because they cause the organs, typically the liver, to release extra copper into the bile, which carries copper, waste products, and toxins to the digestive tract and excrete. Once in the bloodstream, it can be removed from the body via the kidneys. Wilson's disease is caused by disruptions or changes (mutations) in the ATP7B gene, which is involved in the transfer of excess copper from the liver to the bile, where it is eventually excreted from the body via the intestines.
Wilson's Disease Treatment Market
The global is expected to be worth US$ 527.0 million in 2022, with a CAGR of 6.2% during the forecast period (2022-2030).
Leading Companies in the Wilson's Disease Treatment Industry:
1. Valeant Pharmaceuticals International, Inc.
Bausch Health Companies Inc. is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. It creates, manufactures, and sells branded generic drugs and pharmaceutical products, primarily for skin diseases, gastrointestinal disorders, eye health, and neurology.
Syprine, which treats Wilson disease, gained notoriety after Valeant Pharmaceuticals International raised the drug's price to $21,267 in 2015, up from $652 just five years before.
2. Noblepharma Co., Ltd.
Nobel Pharma Co.,Ltd was established in 2003. The Company's primary business is commercial physical and biological research and development.
Nobelpharma is a small Japanese pharmaceutical company dedicated to developing treatments for rare diseases. Small pharma employs a novel approach to treating neglected diseases.
3. Wilson Therapeutics AB
Wilson Therapeutics, based in Stockholm, Sweden, is a biopharmaceutical company that develops novel therapies for patients suffering from rare copper-mediated disorders.